Home

MARKSMAN HEALTHCARE | SCIENTIFIC OUTSOURCING AND RESEARCH CONSULTING

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.

MarksMan Healthcare Communications, a non-profit division of path finders charitable trust, is a scientific outsourcing and research consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilize the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.

Our experienced and trained analytics team provides HEOR, RWE and market access support to large and small life science companies. We also provide services pertaining to “Medical and Scientific Writing, Medical Affairs, Clinical Data Management, Drug Safety and Pharmacovigilance”.

OUR SERVICES

A scientific research consulting committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories.

Evidence, Value & Access

Medical Affairs

Clinical Data Management

Drug Safety & Pharmacovigilance

Scientific Support

Data Curation

LATEST FROM BLOG

04Dec 2017

The idea that money drives our behaviour is so much part of our culture that we rarely step back to think about it. Two-for-one deals on anything from cinema tickets to clothing, cut-price airline tickets or the promise of hefty annual bonuses drive our consumer and work–life choices. So the question arises, why not health […]

04Oct 2017

There’s a huge load on both pharmaceutical industry and academia in terms of data and information that is circulated through documents such as study protocols, reports, investigator brochures, manuscripts, and several other regulatory and marketing publications. Both writers and reviewers of these documents are overwhelmed with data and information overload, more so while adhering to […]

LATEST PRESENTATIONS

  • ISPOR 22nd Annual International Meeting, May 20-24, 2017, Boston, MA, USA

    Efficacy & Safety of Oxaliplatin/Capecitabine Based Chemotherapy Plus Bevacizumab as First-line Treatment for Advanced Colorectal Cancer: A Systematic Review & Meta analysis.

  • ISPOR 19th Annual European Congress, 29 October-2 November 2016, Vienna, Austria

    Safety Profile of Daclizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta Analysis

  • ISPOR 21st Annual International Meeting, May 21-25, 2016, Washington, DC, USA

    Mepolizumab for the Treatment of Chronic Asthma. A Meta-Analysis of Randomized Placebo-Controlled Trials

  • ISPOR 22nd Annual International Meeting, May 20-24, 2017, Boston, MA, USA

    Efficacy & Safety of Oxaliplatin/Capecitabine Based Chemotherapy Plus Bevacizumab as First-line Treatment for Advanced Colorectal Cancer: A Systematic Review & Meta analysis.

  • ISPOR 18 Annual European Congress, 7-11 November, 2015, Milan, Italy

    Comparison of T-piece Resuscitator with Other Flow – Inflating Bags for Providing Positive Pressure Ventilation During Neonatal Resuscitation: A Systematic Review

  • ISPOR 20th Annual International Meeting, May 16 – 20, 2015, Philadelphia, PA, USA

    Efficacy And Safety Of Canagliflozin Among Patients With Type 2 Diabetes Mellitus: A Systematic Review And Meta-Analysis

WHAT OUR CLIENT SAY

OUR COLLABORATIONS